Combinostics at AAN
April 2-7, 2022 | Seattle, WA
Will you be attending the 2022 AAN Annual Meeting?
Schedule some time to learn more about how our cNeuro® suite, including the cMRI™ and cDSI™ applications, supports end-to-end management of patients with neurological disorders, from earlier detection to differential diagnosis and monitoring of treatment outcomes.
Using a combination of science and innovative AI technology, we aim to make a difference in the lives of patients with neurological disorders.
Our cNeuro® suite puts the focus on patients by providing clinicians with objective, systematic insights for confident, evidence-based diagnostic and management decisions.
Patient data from multiple sources are integrated and compared with data from previous patients and healthy controls: demographic information, imaging (cMRI) and other biomarkers, clinical characteristics, and neuropsychology tests.
Applications in the cNeuro® suite:
Our AI-driven software tools support early detection, differential diagnosis, prediction of progression, and monitoring of neurodegenerative disorders.
cMRI provides fully automated brain MRI quantification for increased throughput, greater objectivity, and high-quality reporting for improved patient care.